Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)

L. M. Demeter; R. W. Shafer; P. M. Meehan; J. Holden-Wiltse; Margaret A Fischl; W. W. Freimuth; M. F. Para; R. C. Reichman

doi:10.1128/AAC.44.3.794-797.2000

Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)

L. M. Demeter, R. W. Shafer, P. M. Meehan, J. Holden-Wiltse, Margaret A Fischl, W. W. Freimuth, M. F. Para, R. C. Reichman

Medicine

Research output: Contribution to journal › Article

75 Scopus citations

Abstract

The development of human immunodeficiency virus type 1 resistance to delavirdine (DLV) was studied in subjects receiving DLV monotherapy. Phenotypic resistance developed in 28 of 30 subjects within 8 weeks. K103N and Y181C, which confer nonnucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance, were the predominant reverse transcriptase mutations. P236L, which confers DLV resistance but hypersensitivity to other NNRTIs, developed in <10% of isolates.

Original language	English
Pages (from-to)	794-797
Number of pages	4
Journal	Antimicrobial Agents and Chemotherapy
Volume	44
Issue number	3
DOIs	https://doi.org/10.1128/AAC.44.3.794-797.2000
State	Published - Mar 1 2000

Fingerprint

ASJC Scopus subject areas

Pharmacology (medical)

Cite this

Demeter, L. M., Shafer, R. W., Meehan, P. M., Holden-Wiltse, J., Fischl, M. A., Freimuth, W. W., Para, M. F., & Reichman, R. C. (2000). Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). Antimicrobial Agents and Chemotherapy, 44(3), 794-797. https://doi.org/10.1128/AAC.44.3.794-797.2000

Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). / Demeter, L. M.; Shafer, R. W.; Meehan, P. M.; Holden-Wiltse, J.; Fischl, Margaret A; Freimuth, W. W.; Para, M. F.; Reichman, R. C.

In: Antimicrobial Agents and Chemotherapy, Vol. 44, No. 3, 01.03.2000, p. 794-797.

Research output: Contribution to journal › Article

Demeter, LM, Shafer, RW, Meehan, PM, Holden-Wiltse, J, Fischl, MA, Freimuth, WW, Para, MF & Reichman, RC 2000, 'Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)', Antimicrobial Agents and Chemotherapy, vol. 44, no. 3, pp. 794-797. https://doi.org/10.1128/AAC.44.3.794-797.2000

Demeter LM, Shafer RW, Meehan PM, Holden-Wiltse J, Fischl MA, Freimuth WW et al. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). Antimicrobial Agents and Chemotherapy. 2000 Mar 1;44(3):794-797. https://doi.org/10.1128/AAC.44.3.794-797.2000

Demeter, L. M. ; Shafer, R. W. ; Meehan, P. M. ; Holden-Wiltse, J. ; Fischl, Margaret A ; Freimuth, W. W. ; Para, M. F. ; Reichman, R. C. / Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). In: Antimicrobial Agents and Chemotherapy. 2000 ; Vol. 44, No. 3. pp. 794-797.

@article{4c09a6b474c349449781be463008fdae,

title = "Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)",

abstract = "The development of human immunodeficiency virus type 1 resistance to delavirdine (DLV) was studied in subjects receiving DLV monotherapy. Phenotypic resistance developed in 28 of 30 subjects within 8 weeks. K103N and Y181C, which confer nonnucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance, were the predominant reverse transcriptase mutations. P236L, which confers DLV resistance but hypersensitivity to other NNRTIs, developed in <10% of isolates.",

author = "Demeter, {L. M.} and Shafer, {R. W.} and Meehan, {P. M.} and J. Holden-Wiltse and Fischl, {Margaret A} and Freimuth, {W. W.} and Para, {M. F.} and Reichman, {R. C.}",

year = "2000",

month = mar

day = "1",

doi = "10.1128/AAC.44.3.794-797.2000",

language = "English",

volume = "44",

pages = "794--797",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "3",

}

TY - JOUR

T1 - Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)

AU - Demeter, L. M.

AU - Shafer, R. W.

AU - Meehan, P. M.

AU - Holden-Wiltse, J.

AU - Fischl, Margaret A

AU - Freimuth, W. W.

AU - Para, M. F.

AU - Reichman, R. C.

PY - 2000/3/1

Y1 - 2000/3/1

N2 - The development of human immunodeficiency virus type 1 resistance to delavirdine (DLV) was studied in subjects receiving DLV monotherapy. Phenotypic resistance developed in 28 of 30 subjects within 8 weeks. K103N and Y181C, which confer nonnucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance, were the predominant reverse transcriptase mutations. P236L, which confers DLV resistance but hypersensitivity to other NNRTIs, developed in <10% of isolates.

AB - The development of human immunodeficiency virus type 1 resistance to delavirdine (DLV) was studied in subjects receiving DLV monotherapy. Phenotypic resistance developed in 28 of 30 subjects within 8 weeks. K103N and Y181C, which confer nonnucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance, were the predominant reverse transcriptase mutations. P236L, which confers DLV resistance but hypersensitivity to other NNRTIs, developed in <10% of isolates.

UR - http://www.scopus.com/inward/record.url?scp=0034002944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034002944&partnerID=8YFLogxK

U2 - 10.1128/AAC.44.3.794-797.2000

DO - 10.1128/AAC.44.3.794-797.2000

M3 - Article

C2 - 10681363

AN - SCOPUS:0034002944

VL - 44

SP - 794

EP - 797

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 3

ER -

Access to Document

10.1128/AAC.44.3.794-797.2000